In two separate AD-tau mouse models, ChABC treatment also improved cognitive deficits as assessed by object recognition test and increased field excitatory synaptic potential amplitudes in perirhinal cortex (Yang et al., 2015). Here, MAPT is linked to Alzheimer disease.